AbbVie (ABBV) Assets (2012 - 2026)
AbbVie (ABBV) reported Assets of $136.5 billion for Q1 2026, little changed year-over-year from $136.2 billion in Q1 2025, and up 1.87% on a QoQ basis from $134.0 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Assets data on file, last reported at $136.5 billion in Q1 2026.
- Quarterly Assets changed 0.22% year-over-year to $136.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.5 billion (changed 0.22% YoY) and the FY2025 annual result came in at $134.0 billion, down 0.89% from the prior year.
- Assets rose to $136.5 billion in Q1 2026 per ABBV's latest filing, from $134.0 billion in the prior quarter.
- Across five years, Assets topped out at $148.9 billion in Q1 2024 and bottomed at $133.9 billion in Q3 2025.
- The 5-year median for Assets is $136.5 billion (2026), against an average of $138.5 billion.
- The widest annual swing landed in 2024, when Assets climbed 10.65%; it then declined 8.54% in 2025.
- Tracing ABBV's Assets over 5 years: stood at $138.8 billion in 2022, then fell by 2.95% to $134.7 billion in 2023, then gained by 0.33% to $135.2 billion in 2024, then decreased by 0.89% to $134.0 billion in 2025, then advanced by 1.87% to $136.5 billion in 2026.
- Per Business Quant, the three latest ABBV Assets figures stand at $136.5 billion (Q1 2026), $134.0 billion (Q4 2025), and $133.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 116.58 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 200.89 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 136.46 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 86.48 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 81.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136.46 Bn |
| Dec 31, 2025 | 133.96 Bn |
| Sep 30, 2025 | 133.90 Bn |
| Jun 30, 2025 | 137.18 Bn |
| Mar 31, 2025 | 136.17 Bn |
| Dec 31, 2024 | 135.16 Bn |
| Sep 30, 2024 | 143.42 Bn |
| Jun 30, 2024 | 141.94 Bn |
| Mar 31, 2024 | 148.87 Bn |
| Dec 31, 2023 | 134.71 Bn |
| Sep 30, 2023 | 136.22 Bn |
| Jun 30, 2023 | 135.37 Bn |
| Mar 31, 2023 | 134.54 Bn |
| Dec 31, 2022 | 138.81 Bn |
| Sep 30, 2022 | 141.33 Bn |
| Jun 30, 2022 | 143.19 Bn |
| Mar 31, 2022 | 143.21 Bn |
| Dec 31, 2021 | 146.53 Bn |
| Sep 30, 2021 | 148.86 Bn |
| Jun 30, 2021 | 147.97 Bn |
| Mar 31, 2021 | 150.50 Bn |
| Dec 31, 2020 | 150.57 Bn |
| Sep 30, 2020 | 149.62 Bn |
| Jun 30, 2020 | 149.53 Bn |
| Mar 31, 2020 | 91.20 Bn |
| Dec 31, 2019 | 89.12 Bn |
| Sep 30, 2019 | 59.44 Bn |
| Jun 30, 2019 | 57.14 Bn |
| Mar 31, 2019 | 56.77 Bn |
| Dec 31, 2018 | 59.35 Bn |
| Sep 30, 2018 | 66.16 Bn |
| Jun 30, 2018 | 61.64 Bn |
| Mar 31, 2018 | 69.34 Bn |
| Dec 31, 2017 | 70.79 Bn |
| Sep 30, 2017 | 68.84 Bn |
| Jun 30, 2017 | 66.99 Bn |
| Mar 31, 2017 | 65.66 Bn |
| Dec 31, 2016 | 66.10 Bn |
| Sep 30, 2016 | 66.63 Bn |
| Jun 30, 2016 | 67.21 Bn |
| Mar 31, 2016 | 53.72 Bn |
| Dec 31, 2015 | 53.05 Bn |
| Sep 30, 2015 | 54.83 Bn |
| Jun 30, 2015 | 53.86 Bn |
| Mar 31, 2015 | 26.70 Bn |
| Dec 31, 2014 | 27.51 Bn |
| Sep 30, 2014 | 28.45 Bn |
| Jun 30, 2014 | 29.05 Bn |
| Mar 31, 2014 | 28.66 Bn |
| Dec 31, 2013 | 29.20 Bn |
| Sep 30, 2013 | 28.25 Bn |
| Jun 30, 2013 | 27.91 Bn |
| Mar 31, 2013 | 27.17 Bn |
| Dec 31, 2012 | 27.01 Bn |